Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., et al. (2017). Reducing the global burden of HTLV-1 infection: An agenda for research and action. ANTIVIRAL RESEARCH, 137, 41-48 [10.1016/j.antiviral.2016.10.015].

Reducing the global burden of HTLV-1 infection: An agenda for research and action

MACCHI, BEATRICE;
2017

Abstract

Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14
Settore MED/07 - Microbiologia e Microbiologia Clinica
English
HTLV-1; Leukemia; Oncogene; Retrovirus; Vaccine
Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., et al. (2017). Reducing the global burden of HTLV-1 infection: An agenda for research and action. ANTIVIRAL RESEARCH, 137, 41-48 [10.1016/j.antiviral.2016.10.015].
Willems, L; Hasegawa, H; Accolla, R; Bangham, C; Bazarbachi, A; Bertazzoni, U; Carneiro Proietti, A; Cheng, H; Chieco Bianchi, L; Ciminale, V; Coelho dos Reis, J; Esparza, J; Gallo, R; Gessain, A; Gotuzzo, E; Hall, W; Harford, J; Hermine, O; Jacobson, S; Macchi, B; Macpherson, C; Mahieux, R; Matsuoka, M; Murphy, E; Peloponese, J; Simon, V; Tagaya, Y; Taylor, G; Watanabe, T; Yamano, Y
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
WillemAVR 2017.pdf

non disponibili

Descrizione: articolo principale
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1.65 MB
Formato Adobe PDF
1.65 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/180233
Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 83
social impact